



PSMA in Prostate Cancer

Guest Editor:

Dr. Finn Edler von Eyben

Center of Tobacco Control
Research, 5230 Odense, Denmark

Deadline for manuscript
submissions:

closed (30 September 2021)

Message from the Guest Editor

Prostate Cancer has the second highest mortality for men in Western Societies. Prostate Specific Membrane Antigen (PSMA) is a glycoprotein that is highly expressed in plasma membrane of prostate cancer especially in the most aggressive forms for prostate cancer. In the recent decade PSMA PET/CT has become widely used in diagnostics of patients with metastatic castration-resistant prostate cancer (mCRPC). PSMA PET/CT has a high detection rate even for patients with low values of prostate specific antigen (PSA). Staging with PSMA PET/CT change planned treatment for more than a quarter of the patients. Radioligands can bind to the extracellular part of PSMA. Thereby the radioligand is absorbed into the cancer cells and damage the DNA of the cells. PSMA radioligand therapy is a safe and effective treatment of patients with mCRPC as documented in preliminary results of a randomized trial, TheraP. This issue up-to-date information on the use of PSMA for diagnostics and treatment of patients with prostate cancer. The issue serves as a very useful resource tool for patients, physicians, and researchers dealing with the challenge of mCRPC.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Inorganic Chemistry*)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI